Trajectories of depression symptom improvement and associated predictor analysis: An analysis of duloxetine in double-blind placebo-controlled trials
详细信息 查看全文
- 作者：Hirofumi Tokuokaa ; tokuoka_hirofumi@lilly.com" class="auth_mail" title="E-mail the corresponding author ; Hitoshi Takahashib ; Akichika Ozekic ; Atsushi Kugaa ; Aki Yoshikawad ; Toshinaga Tsujie ; Madelaine M. Wohlreichf
- 关键词：AE ; adverse events ; AUC ; area under the curve ; CI ; confidence interval ; DLX ; duloxetine ; DSM-IV-TR ; Diagnostic and Statistical Manual-IV-Text Revision ; HAM-D ; Hamilton Depression Rating Scale ; HAM-D17 ; 17-item Hamilton Depression Rating Scale ; HAM-D21 ; 21-item Hamilton Depression Rating Scale ; HAM-D24 ; 24-item Hamilton Depression Rating Scale ; LOCF ; last observation carried forward ; MDD ; major depressive disorder ; MMRM ; mixed model repeated measures ; OR ; odds ratio ; PLA ; placebo ; QIDS-C16 ; 16-it
- 刊名：Journal of Affective Disorders
- 出版年：2016
- 出版时间：15 May 2016
- 年：2016
- 卷：196
- 期：Complete
- 页码：171-180
- 全文大小：2315 K
文摘
- •
Trajectories of symptom improvement in patients with MDD were examined.
- •
Ten placebo-controlled trials of duloxetine were included; MDD symptoms were assessed with the HAM-D.
- •
We found different trajectories of improvement in remitters and nonremitters, starting at early time points.
- •
Early improvement on many items of the HAM-D predicted remission.
- •
Early monitoring of some individual symptoms of MDD may be useful in making treatment decisions.